Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

FDA 510(k)

Eversense 365 Continuous Glucose Monitoring (CGM) System

Numéro K : K241335 · 2024-09-16

DemandeurSenseonics, Incorporated
Date de décision2024-09-16
Code produitSBA
Comité consultatifCH
DécisionSubstantially Equivalent

Résumé du dispositif

Eversense 365 Continuous Glucose Monitoring (CGM) System is the device name listed in this FDA 510(k) record. The listed applicant is Senseonics, Incorporated. It received FDA 510(k) clearance on 2024-09-16 under 510(k) number K241335. The device is classified under product code SBA. It was reviewed by the CH advisory panel. FDA Decision: Substantially Equivalent.

Questions fréquentes

What is the Eversense 365 Continuous Glucose Monitoring (CGM) System?

Eversense 365 Continuous Glucose Monitoring (CGM) System is a medical device that received FDA 510(k) clearance on 2024-09-16. The listed applicant is Senseonics, Incorporated. The 510(k) number is K241335.

When did Eversense 365 Continuous Glucose Monitoring (CGM) System receive FDA 510(k) clearance?

Eversense 365 Continuous Glucose Monitoring (CGM) System received FDA 510(k) clearance on 2024-09-16, under 510(k) number K241335.

Who is the listed applicant for Eversense 365 Continuous Glucose Monitoring (CGM) System?

The FDA 510(k) record lists Senseonics, Incorporated as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Eversense 365 Continuous Glucose Monitoring (CGM) System?

The FDA product code for Eversense 365 Continuous Glucose Monitoring (CGM) System is SBA.

Essais cliniques associés

Les enregistrements connexes sont mis en correspondance automatiquement à l'aide des noms, codes produits ou autres métadonnées. Une mise en correspondance n'établit pas de relation clinique, scientifique, corporative ou réglementaire vérifiée ; veuillez consulter les sources officielles liées.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Source officielle

Voir dans la base de données FDA →

Données issues de l'API ouverte de la FDA. Pour les informations les plus récentes et faisant autorité, veuillez toujours vous référer au registre officiel.

↑